September 2023

CUTISS launches Series C financing round to advance the development of its personalized skin technology, paving the way towards commercialization

Switzerland, 18 September 2023 – CUTISS AG, a Swiss clinical-stage life sciences company focused on skin regenerative medicine and tissue engineering, has announced the launch of its Series C for the next stage of the company’s development. CUTISS seeks to raise the Series C with the participation of existing and new investors to take its personalized skin […]

CUTISS launches Series C financing round to advance the development of its personalized skin technology, paving the way towards commercialization Read More »

CUTISS recognized as leading biotech in TOP100 Swiss Startup Award

Awards / jackie.vuistiner

In this year’s 13th edition of the TOP100 Swiss Startup Award, CUTISS has been recognized as a ‘most promising’ TOP 25 scale-up. We are just as proud to say that CUTISS continues to place 1st in the Biotech category, this year amongst the scale ups! For this year’s listing, CUTISS was selected by a jury

CUTISS recognized as leading biotech in TOP100 Swiss Startup Award Read More »

GEN interview

Media / jackie.vuistiner

Genetic Engineering & Biotechnology News (GEN), the leading life sciences publication, recently interviewed our CEO Daniela Marino. The article reports on CUTISS’s progress with denovoSkin™ and the clinical trials, how the company plans to restore patients’ own skin pigmentation, the key role of automation to meet the scale up challenge, and CUTISS’s global ambitions. “The product

GEN interview Read More »

September 2023

CUTISS launches Series C financing round to advance the development of its personalized skin technology, paving the way towards commercialization

CUTISS recognized as leading biotech in TOP100 Swiss Startup Award

GEN interview

Contact Us

Main Office / R&D / GMP Laboratories

Main office / R&D / GMP Laboratories

Newsletter